Erratum to: Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study (npj Aging and Mechanisms of Disease, (2017), 3, 1, (17), 10.1038/s41514-017-0016-9);Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study

npj Aging and Mechanisms of Disease

Volumn 3, Issue 1, 2017, Pages

  Dellinger, Ryan W ^a   Santos, Santiago Roel ^a   Morris, Mark ^a   Evans, Mal ^b   Alminana, Dan ^a   Guarente, Leonard ^a,c   Marcotulli, Eric ^a  

^a Elysium Analytics Inc   (United States)

^b KGK Synergize   (Canada)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85045569694     PISSN: None     EISSN: 20563973     Source Type: Journal    
DOI: 10.1038/s41514-018-0027-1     Document Type: Erratum

References (34)

1. Imai, S., Armstrong, C. M., Kaeberlein, M. & Guarente, L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403, 795–800 (2000).
2. Bonkowski, M. S. & Sinclair, D. A. Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds. Nat. Rev. Mol. Cell. Biol. 17, 679–690 (2016).
3. Guarente, L. Calorie restriction and sirtuins revisited. Genes Dev. 27, 2072–2085 (2013).
4. + and sirtuins in aging and disease. Trend. Cell Biol. 24, 464–471 (2014).
5. Chang, H. C. & Guarente, L. SIRT1 and other sirtuins in metabolism. Trend. Endocrinol. Metab. 25, 138–145 (2014).
6. + in fungi and humans. Cell 117, 495–502 (2004).
7. Trammell, S. A. et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat. Commun. 7, 12948 (2016).
8. Ramsey, K. M., Mills, K. F., Satoh, A. & Imai, S. Age-associated loss of Sirt1-mediated enhancement of glucose-stimulated insulin secretion in beta cell-specific Sirt1-overexpressing (BESTO) mice. Aging Cell 7, 78–88 (2008).
9. Mouchiroud, L., Houtkooper, R. H. & Auwerx, J. NAD(+) metabolism: a therapeutic target for age-related metabolic disease. Crit. Rev. Biochem. Mol. Biol. 48, 397–408 (2013).
10. Massudi, H. et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS ONE 7, e42357 (2012).
11. Zhu, X. H., Lu, M., Lee, B. Y., Ugurbil, K. & Chen, W. In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences. Proc. Natl Acad. Sci. USA 112, 2876–2881 (2015).
12. Canto, C., Menzies, K. J. & Auwerx, J. NAD(+) Metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab. 22, 31–53 (2015).
13. Gomes, A. P. et al. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell 155, 1624–1638 (2013).
14. Zhang, H. et al. NAD(+) repletion improves mitochondrial and stem cell function and enhances life span in mice. Science 352, 1436–1443 (2016).
15. + replenishment improves lifespan and healthspan in Ataxia Telangiectasia models via mitophagy and DNA repair. Cell Metab. 24, 566–581 (2016).
16. Scheibye-Knudsen, M. et al. A high-fat diet and NAD(+) activate Sirt1 to rescue premature aging in cockayne syndrome. Cell Metab. 20, 840–855 (2014).
17. Canto, C. et al. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 15, 838–847 (2012).
18. Yoshino, J., Mills, K. F., Yoon, M. J. & Imai, S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 14, 528–536 (2011).
19. Frederick, D. W. et al. Loss of NAD homeostasis leads to progressive and reversible degeneration of skeletal muscle. Cell Metab. 24, 269–282 (2016).
20. Hubbard, B. P. & Sinclair, D. A. Measurement of sirtuin enzyme activity using a substrate-agnostic fluorometric nicotinamide assay. Methods Mol. Biol. 1077, 167–177 (2013).
21. Neves, A. R., Lucio, M., Lima, J. L. & Reis, S. Resveratrol in medicinal chemistry: a critical review of its pharmacokinetics, drug-delivery, and membrane interactions. Curr. Med. Chem. 19, 1663–1681 (2012).
22. McCormack, D. & McFadden, D. A review of pterostilbene antioxidant activity and disease modification. Oxid. Med. Cell Longev. 2013, 575482 (2013).
23. Kapetanovic, I. M., Muzzio, M., Huang, Z., Thompson, T. N. & McCormick, D. L. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother. Pharmacol. 68, 593–601 (2011).
24. Dellinger, R. W., Garcia, A. M. & Meyskens, F. L. Jr. Differences in the glucuronidation of resveratrol and pterostilbene: altered enzyme specificity and potential gender differences. Drug Metab. Pharmacokinet. 29, 112–119 (2014).
25. Riche, D. M. et al. Analysis of safety from a human clinical trial with pterostilbene. J. Toxicol. 2013, 463595 (2013).
26. Guarente, L. Sir2 links chromatin silencing, metabolism, and aging. Genes Dev. 14, 1021–1026 (2000).
27. Guarente, L. & Franklin, H. Epstein lecture: sirtuins, aging, and medicine. N. Engl. J. Med. 364, 2235–2244 (2011).
28. Conze, D.B., Crespo-Barreto, J. & Kruger, C.L. Safety assessment of nicotinamide riboside, a form of vitamin B3. Hum. Exp. Toxicol. 35, 1149–1160 (2016).
29. Riche, D. M. et al. Pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial. Evid. Based Complement Alternat. Med. 2014, 459165 (2014).
30. Marcovina, S. M., Gaur, V. P. & Albers, J. J. Biological variability of cholesterol, triglyceride, low- and high-density lipoprotein cholesterol, lipoprotein(a), and apolipoproteins A-I and B. Clin. Chem. 40, 574–578 (1994).
31. Raatz, S. K., Johnson, L. K., Rosenberger, T. A. & Picklo, M. J. Twice weekly intake of farmed Atlantic salmon (Salmo salar) positively influences lipoprotein concentration and particle size in overweight men and women. Nutr. Res. 36, 899–906 (2016).
32. Backes, J., Anzalone, D., Hilleman, D. & Catini, J. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. Lipids Health Dis. 15, 118 (2016).
33. Mukherjee, S. et al. Nicotinamide adenine dinucleotide biosynthesis promotes liver regeneration. Hepatology 65, 616–630 (2016).
34. Gariani, K. et al. Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice. Hepatology 63, 1190–1204 (2016).